

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Paxlovid and hospitalisations, continuing COVID-19 waves, risk of long COVID with Delta and Omicron, mRNA vaccines for under-5s

Peer reviewed journals featured:

- A narrative review on smartphone apps in the COVID-19 pandemic [here](#)
- Observational studies on:
 - COVID-19 hospitalisation and ED visits after paxlovid treatment [here](#)
 - Maternal vaccination and risk of hospitalisation for COVID-19 among infants [here](#) and associated editorial [here](#)
 - Neuropsychiatric symptoms after COVID-19 hospitalisation [here](#)
 - Pandemic differences across the four UK nations [here](#)
 - Impact of COVID-19 on asthma exacerbations in England [here](#)
 - Telemedicine for outpatient palliative care during COVID-19 [here](#)
 - Rapid evaluation of vaccine effectiveness against SARS-CoV-2 variants [here](#)
 - Patterns of social mixing in England during different levels of restrictions [here](#)
- Commentary on the continuation of COVID-19 waves [here](#)

Letters and correspondence discussed:

- Risk of long COVID associated with Delta versus Omicron variants [here](#)
- Neutralisation escape by Omicron subvariants BA.2.12.1, BA.4, and BA.5 [here](#)
- SARS-CoV-2 evolution and immune escape in immunocompromised patients [here](#)
- Evaluation of acute adverse events after COVID-19 vaccination during pregnancy [here](#)
- Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection [here](#)
- Effectiveness of homologous and heterologous COVID-19 boosters against Omicron [here](#)

Pre-peer review articles featured:

- Global estimates of the fitness advantage of Omicron variant [here](#)
- Outcomes of SARS-CoV-2 reinfection [here](#)
- Cardiopulmonary exercise testing to evaluate post-acute sequelae of COVID-19 (long COVID) [here](#)
- Sotrovimab for preventing hospitalisation and mortality in outpatients during Omicron [here](#)
- Characterising patterns of COVID-19 and long COVID symptoms in the UK [here](#)

- Prevalence and severity of symptoms 3 months after SARS-CoV-2 infection compared to test-negative and population controls in the Netherlands [here](#)

Guidance and reports

- The World Health Organization updated its mass gathering COVID-19 risk assessment tool [here](#)

News and blogs

- Long COVID risk is lower with Omicron than Delta [here](#)
- The US CDC and FDA approve Pfizer and Moderna vaccines for under 5s [here](#) and [here](#)
- Omicron sub variants driving new wave of infections in UK [here](#)
- How months-long COVID infections could seed dangerous new variants [here](#)
- How common is long COVID? [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(long COVID\)](#), [surgery and COVID-19](#), and [rapid testing](#).